Coeptis Therapeutics Holdings Inc.
COEP evidence brief
What we can confirm
- BioSniper Score:
- 4.0 / 10
- Market Cap:
- $102.1M
- Lead Asset:
- CD38-Diagnostic (Preclinical)
What it means
What to watch
Prepared research question
What matters most for COEP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COEP
Coeptis Therapeutics Holdings Inc. is a biotechnology company focused on product development and the commercialization of therapeutic technologies, alongside a technology segment providing lead generation and webinar services.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$102.1M
Cash Runway
—
Lead Asset
CD38-Diagnostic (Preclinical)
Next Catalyst
—
Tracking 3 pipeline candidates for Coeptis Therapeutics Holdings Inc..
Coeptis Therapeutics Holdings Inc. is a biotechnology company focused on product development and the commercialization of therapeutic technologies, alongside a technology segment providing lead generation and webinar services.
- As of 2026-03-31, the company reported cash and equivalents of $5.2 million, total revenue of $0.1 million, and a net loss of $4.0 million [sec].
- The company's biotechnology segment is primarily engaged in product development, capital raising, and infrastructure building, while its technology segment operates the NexGenAI Affiliates Network [sec_mda].
- Management aims to commercialize its target products or technologies through partnerships or other strategic arrangements [sec_mda].
- The company has reported a history of losses and has disclosed that there is substantial doubt regarding its ability to continue as a going concern [sec_mda].
Risks & what to watch (3)›
Key risks
- Going concern uncertainty — There is substantial doubt about the company's ability to continue as a going concern [sec_mda].
- Clinical trial delays — Difficulties in patient enrollment or trial design may delay regulatory approval of product candidates [sec_mda].
- Financial performance — The company has a history of losses and may not achieve or maintain future profitability [sec_mda].
What to watch
- Progress in drug development and potential commercialization partnerships [sec_mda].
- Ability to maintain listing requirements on the Nasdaq Capital Market [sec_mda].
- Management of operating expenses and capital requirements for ongoing research and development [sec_mda].
Sources: SEC filings · SEC MD&A · Generated June 27, 2026 · How we verify sources →
Run Coeptis Therapeutics Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Coeptis Therapeutics Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 20, 2026- % of float
- 7.0%
- Days to cover
- 7.9
- Shares short
- 376,288
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COEP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Coeptis Therapeutics Holdings Inc.?
Coeptis Therapeutics Holdings Inc. is a biotechnology company focused on product development and the commercialization of therapeutic technologies, alongside a technology segment providing lead generation and webinar services.
What is Coeptis Therapeutics Holdings Inc.'s lead drug candidate?
Coeptis Therapeutics Holdings Inc.'s most advanced tracked candidate is CD38-Diagnostic (Preclinical) for In vitro diagnostic tool to analyze if cancer patients might be appropriate candidates for anti-CD38 monoclonal antibody therapy; intended for B cell malignancies with high CD38 expression including multiple myeloma.
Who is the CEO of Coeptis Therapeutics Holdings Inc.?
Mr. David Mehalick is the chief executive officer of Coeptis Therapeutics Holdings Inc. (COEP).
Where is Coeptis Therapeutics Holdings Inc. headquartered?
Coeptis Therapeutics Holdings Inc. (COEP) is headquartered in Wexford, PA, United States.
What therapeutic areas does Coeptis Therapeutics Holdings Inc. focus on?
Coeptis Therapeutics Holdings Inc. develops therapies across Oncology, Neurology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.